FINAL HOURS: Lock in your InvestingPro subscription for 50% off before sale ends
Investing.com - H.C. Wainwright raised its price target on DiaMedica Therapeutics Inc. (NASDAQ:DMAC) to $12.00 from $10.00 on Friday, while maintaining a Buy rating on the stock. Currently trading at $3.93, the clinical-stage biotech company with a market cap of $169 million has seen an impressive 8% gain over the past week. According to InvestingPro data, analyst targets range from $8.00 to $11.00, suggesting significant upside potential.
The price target increase follows positive interim results from Part 1a of the company’s Phase 2 study of DM199 (rinvecalinase alfa) for preeclampsia treatment. The study met pre-specified efficacy and safety endpoints during dose escalation testing. With an overall Financial Health score of "FAIR" according to InvestingPro, the company appears well-positioned to continue its clinical development program.
Key findings included dose-dependent reductions in blood pressure, with the highest dosing achieving the greatest mean blood pressure reductions at 5-minutes post-infusion. Pooled cohorts for the potential therapeutic dose range showed statistically significant blood pressure reductions at multiple time points: 5-minutes, 30-minutes, and 24-hours post-infusion.
The study demonstrated no placental transfer across all cohorts, which H.C. Wainwright highlighted as "paramount to the DM199 safety profile." There were no early labor inductions and no treatment discontinuations reported.
The data also showed evidence of improved uterine artery blood flow, with a statistically significant 13.2% reduction in pulsatility index at the 2-hour mark (p=0.0003), suggesting enhanced placental perfusion. DiaMedica maintains a strong financial position with more cash than debt and a healthy current ratio of 8.02. Get deeper insights into DiaMedica’s financial health and access exclusive analysis with InvestingPro, where you’ll find comprehensive research reports and additional ProTips.
In other recent news, DiaMedica Therapeutics Inc. reported its first-quarter 2025 earnings, surpassing analysts’ expectations with an earnings per share of -0.18, compared to the forecasted -0.20. Despite this earnings beat, the company’s revenue remained at zero, consistent with forecasts. In clinical developments, DiaMedica announced positive interim results from its Phase 2 study of DM199 for preeclampsia, showing significant reductions in blood pressure and improved uterine blood flow. This promising progress has led the company to continue with enrollment in further study cohorts. Additionally, H.C. Wainwright reaffirmed its Buy rating for DiaMedica with a $10 price target, highlighting the potential of DM199 as a disease-modifying therapy for preeclampsia. The company also shared outcomes from its 2025 Annual General Meeting, including the re-election of board members and the appointment of Baker Tilly US, LLP as the independent registered public accounting firm. DiaMedica continues to advance its clinical programs and strengthen its financial position, with a cash runway projected into the third quarter of 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.